Cinobufacini ameliorates experimental colitis via modulating the composition of gut microbiota.

Yongfeng BaiSiwei WangWenkai XuYuanyuan WengShengmei ZhuHao ShengJin ZhuFeng Zhang

Published in: PloS one (2019)

Cinobufacini prevents colitis in mice by modifying the composition and function of gut microbiota. The current study provides additional mechanistic insight in the therapeutic effect of cinobufacini treatment and may pave the way for clinical application of cinobufacini in colitis therapy.

Keyphrases

ulcerative colitis
mouse model
signaling pathway
high fat diet induced
type diabetes
combination therapy
replacement therapy
skeletal muscle